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ABSTRACT 
Sleep-wake disturbances are frequently observed in stroke patients and are associated with 
poorer functional outcome. Until now the effects of sleep on stroke evolution are unknown. 
The purpose of the present study was to evaluate the effects of three sleep deprivation (SD) 
protocols on brain damages after focal cerebral ischemia in a rat model. 
Permanent occlusion of distal branches of the middle cerebral artery was induced in adult rats. 
The animals were then subjected to 6h SD, 12h SD or sleep disturbances (SDis) in which 3 x 
12h sleep deprivation were performed by gentle handling. Infarct size and brain swelling were 
assessed by Cresyl violet staining, and the number of damaged cells was measured by 
terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) staining. 
Behavioral tests, namely tape removal and cylinder tests, were performed for assessing 
sensorimotor function. 
In the 6h SD protocol, no significant difference (P > 0.05) was found either in infarct size 
(42.5 ± 30.4 mm3 in sleep deprived animals vs. 44.5 ± 20.5 mm3 in controls, mean± s.d.), in 
brain swelling (10.2 ± 3.8% in sleep deprived animals vs. 11.3 ± 2.0% in controls) or in 
number of TUNEL-positive cells (21.7 ± 2.0/mm2 in sleep deprived animals vs. 23.0 ± 
1.1/mm2 in controls). In contrast, 12h sleep deprivation increased infarct size by 40 % (82.8 ± 
10.9 mm3 in SD group vs. 59.2 ± 13.9 mm3 in control group, P = 0.008) and number of 
TUNEL-positive cells by 137% (46.8 ± 15/mm2 in SD group vs. 19.7 ± 7.7/mm2 in control 
group, P = 0.003). There was no significant difference (P > 0.05) in brain swelling (12.9 ± 6.3 
% in sleep deprived animals vs. 11.6 ± 6.0 % in controls). The SDis protocol also increased 
infarct size by 76% (3 x 12h SD 58.8 ± 20.4 mm3 vs. no SD 33.8 ± 6.3 mm3, P = 0.017) and 
number ofTUNEL-positive cells by 219% (32.9 ± 13.2/mm2 vs. 10.3 ± 2.5/mm2, P = 0.008). 
Brain swelling did not show any difference between the two groups (24.5 ± 8.4 % in SD 
group vs. 16.7 ± 8.9 % in control group, p > 0.05). Both behavioral tests did not show any 
concluding results. 
In summary, we demonstrate that sleep deprivation aggravates brain damages in a rat model 
of stroke. Further experiments are needed to unveil the mechanisms underlying these effects. 
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1. INTRODUCTION 
Stroke is one of the leading causes of disability in high-income countries and of death 
worldwide 1• According to the World Health Organization, a stroke is defined as "rapidly 
developing clinical signs of focal disturbance of cerebral function, lasting more than 24 hours 
or leading to death with no apparent cause other than that of vascular origin"2 . Stroke is more 
prevalent in men than in women3 and the mean age of stroke patient is 69.8 years for men and 
74.8 years for women4. Ischemic stroke is the consequence of a transient or permanent 
reduction in cerebral blood flow and affects specifically the territory of a major brain artery. 
The reduction in blood flow is due, in the majority of cases, to either an embolus or a local 
thrombosis that occludes a cerebral arteri. 
There are only few medical interventions available. Among these, intravenous thrombolysis 
with alteplase is the most effective treatment in the acute phase (within 4.5 hours/. Patients 
that are not eligible for the intravenous thrombolysis may be candidates for intra-arterial 
thrombolysis if they are evaluated within 6 hours of symptoms. For both of these treatments, 
the major risk is symptomatic brain hemorrhage7 . Unfortunately, functional recovery is, for 
most of the time, incomplete and therefore it is of great importance to find ways to improve 
stroke treatment. 
Several risk factors exist and can be classified depending on whether it is modifiable or not. 
Nonmodifiable risk factors comprise age, ethnicity, sex, low birth weight, and family history 
of stroke. Modifiable risk factors include cardiovascular disease, hypertension, cigarette 
smoking, diabetes, carotid artery stenosis, atrial fibrillation, dyslipidemia, poor diet, obesity, 
physical inactivity, and postmenopausal hormone therapy3• Another risk factor, that is often 
underestimated but nevertheless important, is sleep-wake disturbances. 
Sleep-wake disturbances (SWD) are frequently observed in stroke patients, with a prevalence 
of about 20 to 40 %. Excessive daytime sleepiness, increased sleep needs (hypersomnia) and 
insomnia are the most frequent ones. Several causes are involved in SWD. Brain damage 
itself can disrupt mechanisms underlying the regulation of sleep-wake cycles. Furthermore, 
consequences of stroke, such as pain, increased bed rest, stress, hypoxia or hospital 
environment itself may also influence sleep. SWD have been shown to have adverse 
consequences on cognitive and neurological functions, and finally on quality of life8. Many 
research groups have evaluated the effects of stroke on sleep with the use of 
electroencephalogram (EEG). Several studies have reported augmented wakefulness after 
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9 13 1 1 · 11 -13 d d NREM sleep onset9-12 , reduced sleep efficiency - , reduced tota s eep t1me , ecrease 
sleep stage 2 and slow-wave sleep 11 13 • It is therefore of great importance to recognize and 
treat, when possible, these sleep disturbances in stroke patients. 
Stroke induces a cascade of mechanisms that account for brain damage, such as energy 
failure, excitotoxicity, peri-infarcts depolarizations, inflammation and apoptosis5 14 • Reduction 
of cerebral blood flow diminishes the delivery of substrates, like oxygen or glucose, necessary 
for the tissue surviving. In the absence of energy, ionic gradients are not maintained, 
membrane potential is lost and subsequently leads to depolarization of neurons. Glutamate is 
released, activates its specific receptor, which allows Ca+ and Na+ ions to enter into the cell. 
Water follows passively Na+ ions into the cell and oedema develops. Further to the increase of 
intracellular Ca+ and Na+, K+ and glutamate diffuse in the extracellular space and generate 
waves of depolarization called "peri-infarcts depolarizations". The overload of intracellular 
ca+ activates several enzymes, such as proteases or lipases, which trigger cellular membrane 
degradation and free radicals production. The latter activate inflammatory mediators, which 
lead to leukocytes infiltration and to microglial activation. Free radicals also induce 
mitochondrial and DNA damage, which then induce apoptosis. 
Sleep deprivation studies have shown several roles of sleep. For example, Magistretti's group 
revealed effects of sleep deprivation on glycogen metabolism in cerebral cortex of mice. They 
found increased expression of glucose transporter 1 (Glutl) and protein targeting to glycogen 
(PTG) genes, as well as enhanced glycogen synthase activity (GSynt). These results indicate 
an increased glucose entry into the brain and augmented glycogen synthesis. As glycogen is, 
for the most part, localized in astrocytes, it has been postulated that these cells are involved in 
the regulation of brain energy metabolism during sleep-wake cycle15 16 • Another consequence 
of sleep deprivation was shown by V g~ntzas and co-workers. They studied effects of mild 
chronic sleep restriction in young and healthy subjects. They have found, among others, that 
sleep deprivation increased secretion of pro-inflammatory cytokines, in particular IL-6 and 
TNF-a17. Some evidence indicates that neurotransmitter activities are also influenced by 
sleep. Indeed, homeostasis of extracellular glutamate is regulated by sleep-wake cycles. 
During waking and REM sleep, glutamate levels increased, and during NREM sleep it 
progressively decreased18 . Taken together, these studies suggest an effect of sleep on several 
brain mechanisms like energy metabolism, cytokine production and neurotransmitter 
activities. 
Up to now, there is a lack of knowledge about SD and stroke. The purpose of this study was 
to investigate, in a rat model of focal cerebral ischemia, the effects of three protocols of sleep 
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deprivation on the stroke-induced brain damage. Part of results obtained from this study has 
recently been published 19 • 
2. MATERIALS AND METHODS 
2.1 Animals 
Adult male Sprague-Dawley (Harlan, Netherlands) rats weighing 300-365 gat time of surgery 
were used. They were housed in Plexiglas cages in a room maintained on a 12-hour light/dark 
cycle (light from 9:00 a.m. to 9:00p.m.). Ambient temperature was 22 ± 0.5°C. They had free 
access to food and water. All experiments were conducted with governmental approval 
according to local guidelines (Kantonales Veterinaramt Zurich, Switzerland) for the care and 
use of laboratory animals. 
2.2 Surgical procedure 
Focal cerebral ischemia was induced by coagulating the distal middle cerebral artery (MCA) 
using a procedure modified from Tamura et al. 20. Rats were anesthesized with 2% Isoflurane 
(30% 02, remainder N20). A 2-cm skin incision was performed midway between the ear and 
eye. The skin is retracted and the parotid gland seen. The temporalis muscle was divided 
vertically and the skull exposed where the frontal bone joins the temporal bone. A 5x5 mm 
area of the bone overlying MCA was thinned with a driller and removed. The dura was 
delicately opened with a fine needle and then retracted. The MCA and its three main branches 
dorsal to the rhinal fissure were occluded by bipolar electrocoagulation. The incision was 
closed with silk suture. Rectal temperature was maintained between 36.5 ± 0.5°C by a warm 
lamp during the entire surgery. Animals were placed back into their cages once they were 
awake from anesthesia. 
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2.3 Sleep deprivation protocols (Fig 1) 
2.3.1 6h SD 
In a first set of experiments, 4 rats were subjected to a six-hour sleep deprivation 24 hours 
after surgety (Fig. 1-A). This was performed by gentle handling (knocking at the cage, giving 
new nesting material, introducing new objects to play with) and under continuous visual 
observation. Two rats were sleep deprived at the same time (each of them in an individual 
cage) and this occurred during light phase (start between 10:00-11:00 a.m.). Control rats (n = 
4) were subjected to the same ischemia surgery but left undisturbed afterward. After sleep 
deprivation rats were decapitated after brief isoflurane anesthesia. Brains were removed, 
immediately frozen on dry ice and stored at- 80°C. Control rats were decapitated at the same 
time point as sleep deprived rats. 
2.3.212h SD 
In a second set of experiments, 6 rats were subjected to a 12-hour sleep deprivation 12 hours 
after surgery (Fig. 1-B). In the control group 6 rats were left undisturbed after induced 
ischemia. Rats were sacrificed and brains collected as explained in the 6h SD protocol. 
2. 3. 3 Sleep disturbance (SDis) 
In a third set of experiments, 6 rats were subjected to three times 12-hour sleep deprivation 
(each separated from 12-hour intervals) 12 hours after surgery (Fig. 1-C). Behavioral tests 
were performed to evaluate sensorimotor deficit after induced cerebral ischemia. They were 
performed 12h (i.e. just before sleep deprivation), 24h (i.e. just after sleep deprivation), 60h 
(i.e. just before sleep deprivation) and 72h (i.e. just after sleep deprivation) after surgery. 
Behavioral tests consisted of a session of cylinder test immediately followed by a first session 
of tape removal test and 40 +/- 10 minutes later by a second one. Controls rats (n = 6) were 
subjected to the same ischemia surgery and behavioral tests (i.e. 12h, 24h, 60h, and 72h after 
surgery) but were left undisturbed in between. At the end of experiment, rats were sacrificed 
"' 
and brains removed as in the first two protocols. 
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2.4 Cylinder test 
This test assesses the motor function by showing the limb-use asymmetry during explorative 
activity. Rats were placed into a transparent Plexiglas cylinder (20 em in diameter and 35 em 
height) localized on a glass tabletop. A mirror was placed below and angled in a way that 
enables to see the rat's paws anytime. The test was recorded via the mirror by a camera with 
slow motion property21 • Animals were placed for one session into the cylinder a few days 
before baseline recordings. Each session lasted 4 minutes. Baseline recording consisted of one 
session in the morning and one in the evening of the day before surgery. Then rats were tested 
12 hours, 24 hours, 60 hours and 72 hours after surgery. Each morning sessions were 
performed at the same time (1 0:00 a.m. +/- 1 hour), as well as the evening sessions (06:00 
p.m. +/- 1 hour). The number of forelimb contact with the cylinder wall or floor was counted 
during vertical or horizontal exploration activities. Then the percentage of asymmetry of each 
forelimb wall contacts was calculated as proposed by Biernaskie and co-workers: ([ipsilateral 
paw/(ipsilateral paw+ contralateral paw)] * 1 OOi2• 
2.5 Tape removal test 
The tape removal test assesses both sensory and motor deficit and was performed in an 
adapted manner from the method described by Starkey et al. 23 • As this test was done right 
after the cylinder test, it was also performed in the cylinder. An adhesive tape (L x W: 1.2 x 
0.8 em) was applied to the distal-radial part of the forepaw. The label was attached to either 
the left of right forelimb in a random fashion, and a sense score and a motor score were 
evaluated. The sense score is defined by the time until the rat notices the tape on its paw 
(expressed by shaking of the forepaw and bringing it to the mouth). The motor score is 
defined by the time, once the tape has been noticed, until the rat removes the tape from its 
paw. Each session consisted of 6 trials and each trial lasted 3 minutes maximum. Two 
sessions per day of testing were performed with 40 +/- 10 minutes break in between. First, 
animals had two sessions for habituation a few days before experiment. Then, baseline was 
recorded on the morning and on the evening of the day before surgery. After surgery rats were 
tested at 12 hours, 24 hours, 60 hours and 72 hours. 
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2.6 Brain damage analysis 
Coronal20-r-tm cryostat sections from brain were collected at six levels (+2.70, +1.70, +0.70, 
-0.30, -1.30, -2.30 from Bregma24) for brain damage assessment. Twelve to 15 sections at 
each level were mounted on SuperFrost Plus slides (Menzel GmbH, Braunschweig, Germany) 
for histology assessments. 
Nissl staining was performed to assess infarct area. This histological technique was invented 
by a German neuropathologist named Franz Nissl (1860- 1919). It is a very widely used 
method to study morphology of neurons. It is based on the interaction of a basic dye, like 
cresyl violet, with DNA or RNA present in the cell. As neurons actively synthesize new 
proteins, a high concentration of rough endoplasmic reticulum is found in their cytoplasm and 
therefore, allows a specific staining25 . First, sections were fixed for 20 min at room 
temperature with phosphate-buffered saline (PBS, pH 7.4) containing 4% paraformaldehyde 
and then washed with distilled water. Slides were then dipped successively in the following 
solutions: cresyl violet solution (1 g cresyl violet acetate in 100 ml dH20 containing 0.25 ml 
glacial acetic acid) for 2 min, distilled water (30 sec), 70% ethanol (30 sec), 90% ethanol (30 
sec), 95% ethanol (30 sec), 100% ethanol (30 sec), xylol (2 x 2 min). Finally, sections were 
covered. On digitized cresyl violet slides (Figure 2), infarct area was delineated and measured 
with the NIH imageJ software (NIH, Bethesda, MD, USA) and infarct volume was converted 
with the known distance between each of the chosen levels and eventually corrected for 
oedema by multiplying the ratio of the contralateral to ipsilateral volume26 . Brain edema was 
calculated according to the formula from Kotani et al.: (infarct volume + ipsilateral 
undamaged volume contralateral volume) x 1 00/contralateral volume (% )27 . 
Terminal deoxynucleotidyl transferase mediated dUfP nick end labeling (TUNEL) staining 
was used for detection and quantification of apoptosis at the single-cell level. The principal 
feature of apoptosis is DNA fragmentation. These DNA breaks can be detected by labeling 
free 3'0H ends with modified nucleotides (like biotin-dUTP, digoxigenin-dUTP or 
fluorescein-dUTP) by the mean of an enzyme named terminal deoxynucleotidyl transferase 
(TdTi8 29 . In our case, we used the In Situ Cell Death Detection Kit, Fluorescein (Roche, 
Basel, Switzerland) and visualized sections by fluorescence microscopy. Fluorescein is a 
green dye, which has an excitation wavelength at 494 nm and an emission wavelength at 521 
,: 
nm. Sections were first fixed with 4% paraformaldehyde and then washed 3 x 5 minutes with 
PBS. After 2 minutes incubation on ice in permeabilisation solution PI (1 g NaCitrat in 1000 
9 
ml PBS+ 1 ml Triton X-100, pH 7.4), slides were immersed in 200 ml 0.1 M Citrat Buffer P2 
(pH 6.0) and irradiated 1 minute with 750 W high microwave. For rapid cooling, 80 ml 
double distilled water at room temperature was applied. Sections were then transferred into 
PBS at room temperature before 30 minutes immersion in blocking solution Buffer A (2 ml 
NGS 100 %, 200 ~-tl Gelatine, 60 ~-tl Triton X-100, 200 !-tg bovine serum albumin (BSA), 
17.540 ml PBS). 50 !-tl of TUNEL reaction mixture were applied to each section for 60 
minutes incubation at 3 7 oc in a humidified atmosphere in the dark. Then slides were rinsed 3 
times in PBS for 5 minutes each. Sections were finally counterstained with 4' ,6-diamidino-2-
phenylindole (DAPI) which has a blue emission (excitation wavelength 358 nm (ultraviolet), 
emission wavelength 461 nm). DAPI was applied for 3 to 5 minutes before covering slides. 
Sections were then evaluated under a fluorescent microscope and the number of TUNEL 
positive cells was counted in the injured area measuring 20 mm2 (Figure 3). 
2. 7 Statistics 
Data were presented as mean ± standard deviation (s.d.). The significance of differences in 
means of infarct volume, number of TUNEL positive cells and brain swelling was assessed by 
independent t-test. Tape removal and cylinder tests were evaluated by repeated-measures 
ANOVA (SPSS, 12.02 for Windows) followed by post-hoc independent t-test. The 
significance level was set at P values< 0.05. 
3. RESULTS 
3.1 6-hour sleep deprivation protocol 
Brain damage induced by MCA occlusion was confined to primary sensorimotor cortex. No 
significant difference (P = 0.9) in infarct volume was found between the two groups. Infarct 
size was 42.5 ± 30.4 mm3 (mean ± s.d.) in sleep deprived animals vs. 44.5 ± 20.5 mm3 in 
controls (Figure 4 A). 
TUNEL staining for cell death showed 21.7 ± 2.0/mm2 damaged cells in SD group vs. 23.0 ± 
1.1/mm2 in control group (Figure 4 B). This difference was not significant (P = 0.3). 
Brain swelling was 10.2 ± 3.8 % in sleep deprived animals vs. 11.3 ± 2.0 % in controls 
(Figure 4 C). Here again there was no significant difference (P = 0.6) between the two groups. 
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3.2 12-hour sleep deprivation protocol 
Cresyl violet staining showed a significantly (P = 0.008) increased infarct size in the sleep 
deprivation group (82.8 ± 10.9 mm3 in sleep deprived animals vs. 59.2 ± 13.9 mm3 in 
controls) (Figure 4 A). Infarct size was increased by 40 %. 
The number ofTUNEL-positive cells was significantly (P = 0.003) increased in the SD group 
(46.8 ± 15/mm2) compared with the control group (19.7 ± 7.7/mm2) (Figure 4 B). The number 
of damaged cells was increased by 137 %. 
No significant difference (P = 0.7) in brain swelling was seen between the two groups. 
Swelling was 12.9 ± 6.3 % in sleep deprived animals vs. 11.6 ± 6.0 % in controls (Figure 4 
C). 
3.3 Sleep disturbance protocol 
With this protocol, there was a significant difference (P = 0.017) for the infarct size between 
the sleep deprived group (58.8 ± 20.4 mm3) and the control group (33.8 ± 6.3 mm3) (Figure 4 
A). The infarct size was increased by 76 %. 
TUNEL positive staining also showed a significant (P = 0.008) increase by 219 % in the 
number of damaged cells in the sleep deprivation group (32.9 ± 13.2/mm2) compared with the 
control group (1 0.3 ± 2.5/mm2) (Figure 4 B). 
There was no significant difference (P = 0.1) concerning swelling between the two groups 
(24.5 ± 8.4% in sleep deprived group vs.-16.7 ± 8.9% in control group) (Figure 4 C). 
Results for the cylinder test showed symmetrical use of the forelimbs before ischemia. 
However, after surgery rats from the sleep deprivation group used preferentially their 
unaffected paw for postural support (Figure 5). Repeated-measures ANOVA verified an effect 
of time by group interaction (F4, 40 = 6.399, P < 0.001) and post-hoc independent t-test 
revealed significant differences at 12h, 24h and 60h after surgery. 
Tape removal test revealed deficit after ischemia and sleep deprivation in the sense score but 
not in the motor score. The sense score of sleep-deprived rats was significantly higher for the 
affected forelimb. fndeed, sleep-deprived animals took significantly longer than the control 
group to sense the tape when placed on their affected paw. This impairment persisted 
throughout the whole experiment (repeated-measures ANOVA, time * group, F4,40 = 12.677, 
11 
P = 0.008). Post-hoc independent t-test revealed significant differences at 12h, 24h, 60h and 
72h after surgery. There was no significant difference (P = 0.17) for the sense score in the 
unaffected (left) paw. For the motor score in both left and right paws there was no significant 
difference (P > 0.05). Although the affected (right) motor score showed the tendency to be 
higher for the sleep-deprived group, repeated-measures ANOV A could not verify an effect of 
time by group. 
4. DISCUSSION 
In this study, we evaluated effects of three SD protocols on stroke-induced brain damage in 
the rat. Two protocols, i.e. 12h SD and SDis, induced an increase in infarct volume and 
number ofTUNEL positive cells. In the 12h SD protocol, infarct volume was increased by 40 
% and number of TUNEL positive cells was augmented by 13 7 %. In the SDis protocol 
infarct volume was enhanced by 76 % and number of TUNEL positive cells was increased by 
219 %. This is the first direct demonstration of a negative effect of sleep deprivation on stroke 
pathology. 
In the 6h SD protocol there was no significant difference between the two groups either for 
infarct size or for cell damage. This might be due to two factors in comparison with the 12h 
SD protocol, i.e. the time window chosen for SD and the duration of SD. In the 6h SD 
protocol, SD was started 24 hours after ischemia compared with 12 hours in the 12h SD 
protocol. It has been shown that cells in (or near) the ischemic area are most vulnerable within 
24 hours after onset of ischemia. For example, Garcia et al found major ischemic alterations 
like neuronal swelling, scalloping and neuronal shrinkage until 24 hours post-ischemia30. In 
addition, the duration of SD may also play a role. The 6h SD protocol suggest that sleep 
deprivation as short as 6 hours may be not sufficient to have any influence at the brain cellular 
level. 
We attempted to use the SDis protocol to assess effects of sleep-wake disturbances on stroke 
evolution. Increased sleep needs, insomnia or excessive daytime sleepiness are examples of 
sleep-wake disturbances, which frequently occur after stroke. Sleep and wakefulness are 
regulated by structures in the thalamus, brainstem and posterior hypothalamus. It is therefore 
possible that stoke may lead to such deregulations31 • Indeed, our results suggest that sleep 
disturbances during the acute phase of ischemia may have negative impact on stroke. 
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Many data indicate possible effects of sleep on mechanisms involved in stroke. Ischemic 
stroke is due to a sudden reduction of blood flow, which triggers a series of events (called 
ischemic cascade) including energy failure, excitotoxicity, free radical generation and 
inflammations 14• Short-term sleep deprivation has been shown to affect energy metabolism in 
the brain. Indeed, the level of glucose transporter 1 (Glut 1) gene is enhanced and the activity 
of glycogen synthase (GSynt) increased. This allows an augmented entry of glucose into brain 
parenchyma and favors glycogen synthesis's 16• Other studies reveal increasing brain energy 
consumption after sleep deprivation. Kong et al demonstrated decreasing amount of glycogen 
in gray and white matter of rat brains with sleep deprivation and increasing amount with 
recovery sleep32. Vyazovskiy and co-workers evaluated cortical metabolic rates in mice by 2-
deoxyglucose-uptake measurements: 2-deoxyglucose-uptake decreased after sleep and 
increased when mice where kept awake33 . Short-term sleep deprivation also increases the 
extracellular glutamate concentration18, which could contribute to worsen excitotoxicity. 
Some evidence indicates that long-term sleep deprivation or sleep restriction increases 
secretion of pro-inflammatory cytokines such as IL-6, TNF-a and soluble TNF-a receptor I 
(sTNF-aRI) 17 34 . These cytokines are important mediators in the inflammatory phase of 
cerebral ischemia3s. Several studies have shown that prolonged sleep deprivation decreases 
levels of glutathione and superoxide dismutase, two oxidative stress parameters36-38 . 
Glutathione protects cells against damage induced by free radicals. When its level diminishes, 
equilibrium between reactive oxygen species (ROS) and antioxydant defense mechanisms is 
lose6 . These results suggest that sleep deprivation may induce oxidative stress in brain and by 
doing so could intensify cellular damage in the ischemia site. Taken together, these data show 
that sleep deprivation could aggravate stroke through exacerbation of its pathophysiological 
mechanisms. However, further studies are needed to characterize this functioning. 
Effects of SD on sensorimotor function were evaluated by the mean of two behavioral tests. 
Both tests revealed functional deficits in the affected paw after ischemia and there was also 
group difference. However, these results do not indicate any effect of SD since the group 
difference was already present at 12 hours after ischemia before SD was carried out (Fig. 5 
and 6). As individual difference in both tests was big and the number of animals used in this 
study was relatively small, further experiments with a larger number of animals are needed to 
draw a conclusion about the effects of SD on functional outcomes. 
"'~~ 
In conclusion, this study demonstrates that sleep deprivation occurring early after stroke, 
aggravates brain damage. Thus, improving sleep quality of stroke patients may enhance their 
chance of better outcome. 
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ANNEXEI: 
Figures 1 - 6 
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Figure 1 
A 
Surgery End ofexp. 
I 
v v 
SDgroup SD6h 
Ctrgroup noSD 
0 12 24 30h 
B 
Surgery End ofexp. 
* 
v 
SD group SD12h 
Ctr group noSD 
0 12 24h 
c 
Surgery End ofexp. 
l l 
* * * * 
SD group 
Ctr group 
0 12 24 36 48 60 72b 
Sleep deprivation (SD) protocols: 6h SD (A), 12h SD (B), sleep disturbance (C). The white 
and black bars inctfcate the light and dark period, respectively. (C) asterisks represent 
behavioral tests. (Adapted from Gao et al. 19). 
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Figure 2 
L 1 L2 L3 
L4 L5 L 6 
Nissl Staining: coronal 20-f!m cryostat sections from brain collected at six levels (L 1 to L6 
corresponding to +2.70, +1.70, +0.70, -0.30, -1.30, -2.30 from Bregma). The non stained area 
corresponds to the lesion, which is limited to the somatosensory cortex. 
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Figure 3 
DAPI/TUNEL 
Picture of immunofluorescent stainings of the infarct lesion. 4' ,6-diamidino-2-phenylindole 
(DAPI) staining colours nuclei of all cells in blue (upper left panel). Terminal transferase 
biotinylated-dUTP nick end labeling (TUNEL) staining (green dye) was used to highlights 
apoptotic cells (upper right panel). The down panel represents the double staining DAPI I 
TUNEL. 
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Effects of the 3 different sleep deprivation (SD) protocols on infarct volume (A), number of 
TUNEL positive cells (B), and brain swelling (C) in individual animals. Horizontal bars 
represent the mean values. Independent t-test for each experiment was used for the statistical 
analysis. a, ischemia with sleep deprivation. b, ischemia without sleep deprivation. Picture 
adapted from Gao et al. 19• 
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Figure 5 
Cylinder Test 
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Cylinder test. Percent use of unaffected paw during exploratory activity in a cylinder of sleep 
deprivation (SD) and control (Ctr) group before and after middle cerebral artery occlusion . 
Data are mean ± s.d. (asterisks denote significant difference from Ctr group, P < 0.001, 
repeated-measures ANOVA, independent t-test). 
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Sleep Disruption Aggravates Focal Cerebral Ischemia in the Rat 
Bo Gao, MD1; Ertugrul Cam, DVM1; H. Jaeger1; C. Zunzunegui, MD\ Johannes Sarnthein, PhD3; Claudio L. Bassetti, MD1•2 
1Department of Neurology, University Hospital Ziirich, Switzerland; 2Neurocenter of Southern Switzerland, Lugano, Switzerland; 3Department of 
NeurosurgeiJ', University Hospital Ziirich, Ziirich, Switzerland 
Study Objectives: Sleep changes are frequent in stroke patients and predict a poor outcome. It remains unclear how sleep influences stroke evo-
lution and recovery. We assessed effects of sleep disruption on brain damage and on the expression of axon sprouting genes after focal cerebral 
ischemia in rats. 
Design: 12 h after ischemia induced by occlusion of the middle cerebral artery, rats were subjected to sleep disruption including sleep deprivation 
for 12h (SDpv12h) and sleep disturbances (SDis) by SDpv12h for consecutive 3 days. Control groups included ischemia without SDpv12h or SDis, 
sham surgery plus SDis and sham surgery without SDis. Sleep changes were evaluated based on EEG and EMG recordings. 
Measurements and Results: SDpv12h increased the infarct volume by 40% (SDpv12h 82.8 ± 10.9 vs. control59.2 ± 13.9 mm3, P = 0.008) and 
SDis by 76% (SDis 58.8 ± 20.4 vs. control33.8 ± 6.3 mm3, P = 0.017). SDpv12h also increased the number of damaged cells, visualized by TUNEL 
staining, by 137% (SDpv12h 46.8 ± 15 vs. control19.7 ± 7.7/mm2, P < 0.001) and SDis by 219% (SDis 32.9 ± 13.2 vs. control10.3 ± 2.5/mm2, 
P = 0.002). In addition, SDis significantly elevated the expression of the axonal extension inhibitory molecule neurocan (SDis 14.3 ± 0.4 vs. control 
6.2 ± 0.1-fold of change, P < 0.001) in the injured hemisphere. 
Conclusions: These results provide the first direct evidence for a detrimental impact of sleep disruption on stroke evolution and suggest a potential 
role of sleep modulating treatments on stroke outcomes. 
Keywords: Sleep deprivation, stroke, neuroplasticity, axonal sprouting gene 
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ISCHEMIC STROKE REMAINS ONE OF LEADING 
CAUSES OF DEATH IN INDUSTRIALIZED COUNTRIES 
AND IS ONE OF THE MOST IMPORTANT CAUSES OF 
long-term disability. Sleep disturbances are frequently ob-
served in post-stroke patients and appear to have detrimental 
consequences on neurological deficits, rehabilitation, cognitive 
functions and ultimately on the quality of life. 1-3 It is unknown, 
however, the impact of sleep disruption on ischemia-related 
pathophysiology and plasticity process that determine func-
tional outcome. 
Ischemic stroke, due to a sudden reduction of blood flow, 
triggers a cascade of events, including energy failure, excito-
toxicity, free radical generation, and inflammation.4•5 Evidence 
from sleep deprivation (SDpv) experiments under healthy con-
ditions suggests also fundamental effects of sleep on brain en-
ergy metabolism, neurotransmitter activities and production of 
proinflammatory molecules.6- 11 
After ischemic insults, the injured brain undergoes an ex-
tensive neuronal reconnection and reorganization. 12•13 Axo-
nal sprouting in the peri-infarct area represents an important 
component of the post-stroke brain repair. A set of neuronal 
growth-associated genes has been identified14 to be involved 
in initiating, maintaining and terminating post-stroke axonal 
sprouting that occurs within days after ischemic insult. 15 Our 
recent finding that the sleep stimulant gamma hydroxy butyrate 
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alters expression profiles of neuroplasticity-related genes and 
accelerates stroke recovery 16 suggest that sleep could modulate 
post-stroke brain plasticity at the molecular level. Since SDpv 
has been found to change expression of certain plasticity-re-
lated genes in healthy rodents, 17•18 it is likely that sleep disrup-
tion after stroke could also alter expression of axonal sprouting 
genes. 
The aim of this study was to test the hypothesis in a rat 
model of focal cerebral ischemia that sleep disruption could 
exacerbate brain damage and change expression of genes as-
sociated with axonal sprouting. We focused in this study on 
acute effects of sleep disruption as an initial step to understand 
sleep's role in modulation of stroke recovery. Sleep disruption 
was induced by two protocols, i.e., a short-term SDpv and a 
prolonged sleep disturbance (SDis) over 3 days. For gene ex-
pression assay, we chose a small set of genes whose response 
to stroke is within the first 3 days after insult, such as growth-
promoting genes Gap43 and c-jun, and growth-inhibiting genes 
neurocan, ephrinA5, and ephrinB 1. 14 In this study, assessments 
of brain damage and gene expression were conducted in the 
same brain. 
METHODS 
Animals 
Male Sprague Dawley rats (n =50), 8 weeks old and weight-
ing 200-250g at the time of surgety, were used in this study. 
They were housed under 12-h light/dark cycle (light on 09:00-
21 :00) and ambient temperature at 22 ± 0.5°C. Food and water 
were provided ad libitum. All experiments were conducted with 
governmental approval according to local guidelines (Kan-
tonales Veterinaramt ZUrich, Switzerland) for the care and use 
oflaboratory animals. Effort was made to minimize the number 
of animals used. 
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Electrode Implantations, Data Acquisition, and Vigilance State 
Analysis 
Rats were anesthetized with 2% isoflurane in 30% 0 2 and 
70% Np. Four gold-coated miniature screws (0.9 mm diam-
eter) were insetied in the skull over both sides of the frontal 
cortex (Lateral to midline: 2 mm, Bregma: -2 and +2 mm) to 
record electroencephalogram (EEG). Two EEG electrodes on 
one side of the brain were paired to register EEG from each 
hemisphere. Two gold wires were inserted into neck muscles 
to record electromyogram (EMG). The electrodes were fixed to 
the skull with dental cement. After the surgery, rats were housed 
individually and allowed 7-10 days of recovery. They were then 
connected to recording system by a flexible cable and a swivel. 
Polygraphic recordings were performed with the Embla system 
and the SOMNOLOGICA software (Flaga, Iceland). EEG sig-
nals were sampled at 100 Hz with band-pass filter for low and 
high cut set at 0.3 and none, respectively, and EMG signals at 
200 Hz with band-pass filter for low and high cut set at 10 and 
none, respectively. They were recorded for 8 h (11 :00-19:00) in 
the light phase and 12 h (21 :00-9:00) in the dark phase. 
Vigilance states were scored by visual inspection of 8-s ep-
ochs. Wakefulness (W) was defined by the presence of a desyn-
chronized EEG activity combined with elevated neck muscle 
tone; slow wave sleep (SWS) by high-amplitude slow wave 
EEG activities with a low-EMG and paradoxical sleep (PS) by 
dominant theta frequency activity (6-8 Hz) in EEG with low 
EMG signals. The EEG activity recorded on the contralateral 
hemisphere (i.e., undamaged) to ischemia was mainly used for 
scoring. Whenever there were too many artifacts, the ipsilat-
eral channel was consulted to determine vigilance states. The 
percentage of each state was calculated for 8 h during the light 
(11:00-19:00) and 8 h during dark phase (21:00-5:00). The epi-
sode length for each vigilance states was also computed and 
used for assessing sleep fragmentation. To disregard brief inter-
ruptions of episodes and short episodes, we adopted minimum 
criteria of 12-s episode duration and 8-s episode interruption. 19 
EEG power spectra were computed from 8-s epochs recorded 
on the contralateral hemisphere by custom programming on the 
basis of standard mathematical and signal analysis functions in 
Matlab. We implemented the multi-taper method, which allows 
to trade resolution in the frequency domain for reduced variance. 
Spectra were calculated with a window length of 4 sec, overlap 2 
sec, bandwidth parameter nw = 2 and k = 3 tapers, which offers 
optimal spectral smoothing. The power spectral density was giv-
en in units of 1 O*log 10 (ll V2/Hz). Epochs with artifacts were ex-
cluded by a threshold procedure. The percentage of artifact-free 
epochs during wakefulness was 70 ± 24, 65 ± 18, 64 ± 27, and 71 
± 19 for the 4 experimental groups (see Experimental protocols) 
and 86 ± 15, 82 ± 18, 80 ± 30, and 90 ± 12 during SWS. Spectral 
band power was computed for the frequency bands: delta (1-4 
Hz), theta (4-8Hz), sigma (11-16Hz), and beta (16-25Hz). Delta 
power during SWS was averaged for the first 2 and 8 h for the 
light and the dark phase, and the relative change with respect to 
baseline was computed for corresponding phases. 
INDUCTION OF FOCAL CEREBRAL ISCHEMIA 
After a 24-h baseline polygraphic recording, rats were anes-
thetized with 2% isoflurane (30% 0 2, remainder Np) for the 
ischemia surgery that was carried out with occlusion of the dis-
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tal middle cerebral artery (MCAo ). The procedure was modi-
fied from Tamura et al.20 Briefly, a 2 em vertical skin incision is 
made midway between the ear and eye. The skull was exposed 
where the frontal bone joins the temporal bone. A 5x5 mm area 
of the bone overlying the middle cerebral artery (MCA) was 
removed and the dura retracted. The MCA and its three main 
branches dorsal to the rhinal fissure were occluded by bipolar 
electrocoagulation. The incision was closed with silk suture. 
Sham-control animals were subjected to the same procedure 
except for dura removal and vessel electrocoagulation. Rectal 
temperature was maintained between 36.5 ± 0.5°C by a warm 
lamp during the entire surgery. Animals were placed back into 
their home cages once they were awake from anesthesia. 
Neurologic Assessments 
The animal's motor behavior was carefully evaluated by a 
4-point scale method described by Bederson et alcv21 at 12 h 
after stroke and at the end of experiments. 
Experimental Protocols and Brain Tissue Collection (Figure 1) 
SDpv experiments (Figure JA) SDpv was carried out 12 h 
after the ischemia during the light phase by gently knocking at 
the cage or providing the rats with new playing materials when 
they started showing signs of sleep. SDpv was carried out for 
either 6 h (SDpv 6h) or 12 h (SDpv12h). Control rats (ischemia/ 
without SDpv) were subjected to the same ischemia surgery 
but left undisturbed afterward. Two groups in each experiment 
were used, i.e., ischemia/SDpv 6h (n = 4) and ischemia/without 
SDpv 6 h (n = 4); ischemia/SDpv 12h (n = 6) and ischemia/ 
without SDpv12h (n = 6). At end of experiments, rats were de-
capitated after brief isoflurane anesthesia and brains removed, 
frozen immediately on dry ice and stored at -80°C. Control rats 
were decapitated at the same time point as SDpv rats. 
SDis experiments (Figure 1 B) SDpv12h was carried out as 
described above for 3 consecutive days during the light phase. 
Rats were undisturbed and allowed to sleep during the follow-
ing 12-h dark phase. At the end of the experiment, i.e., 72 h 
after ischemia surgery and around 21 :00, rats were decapitated, 
and brains harvested as described above. One ischemia/SDis 
A 
The SDpv experiment protocol 
Surgery ,!.~===~9~:oo~~~21~:ooj,l.end of exp. SDpv* I SDpv ] 
wlo SDpv w/o SDpv I 
0 12 24h 
B 
The SDis experiment protocol 
L1 L2 L3 
0 12 24 36 48 60 72 h 
-------~~y-~----_j_------~~y_:----- _!_- -~~~ ~---
Figure 1-Schematic of the sleep deprivation (SDpv, A) and sleep 
disturbance (SDis, B) protocols. The white and black bars indicate the 
light and dark period, respectively. *SDpv was carried out for either 6 h 
(SDpv6h) or 12 h (SDpv12h) in separate experiments. 
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group (n = 6) and 3 control groups (n = 6 per group) i.e., isch-
emic/without SDis, sham/SDis, sham/without SDis, were used. 
Plasma Corticosterone Determination 
The plasma corticosterone level was measured in SDpv12h 
and SDis experiments. Blood samples were collected from 
trunk blood at the time when rats were decapitated at the end of 
SDpv (20:30-21 :00, at the end of the light phase, Figure 1) and 
centrifuged with 2500 xg for I 0 min. The plasma corticosterone 
concentration was later determined with Radio ImmunoAssay 
kit (MP Biomedicals, Orangeburg, NY, USA), according to the 
manufacture's instruction. 
Brain Damage Analysis 
For each brain, 20 Jlm sections at 6 brain levels [A= +2.7 
(Ll), + 1.7 (L2), +0.7 (L3), -0.3 (L4), -1.3 (L5), -2.3 (L6) from 
the bregma22 were cut on a cryostat. Twelve to 15 sections at 
the each level were mounted on Super Frost Plus slides (Men-
zel GmbH, Braunschweig, Germany) for histology assessments 
and remaining sections in each level were collected in RNase-
free tubes for gene expression assay (see below). For assessing 
the infarct volume, sections were first fixed with phosphate-
buffered saline (PBS, pH 7.4) containing 4% paraformalde-
hyde for 20 min at room temperature and then performed for 
standard cresyl violet staining. For assessing damaged cells, 
sections fixed with 4% paraformaldehyde were processed 
with terminal transferase biotinylated-dUTP nick end labeling 
(TUNEL) according to the manufacturer's instruction (Roche, 
Basel, Switzerland) to ascertain cells that contain fragmented 
DNA. On digitized cresyl violet sections, the infarct area were 
delineated and measured with the NIH imageJ software (NIH, 
Bethesda, MD, USA), and the infarct volume was converted 
with the known distance between each of the chosen levels and 
eventually corrected for edema by multiplying the ratio of the 
contralateral to ipsilateral volume.23 Brain swelling was calcu-
lated with the formula as follows: [(ipsilateral - contralateral 
hemisphere)/contralateral hemisphere] x 100. The number of 
TUNEL positive cells was counted in the injured area measur-
ing 20 mm2 on sections collected at the level 6. 
Taqman Gene Expression Assay 
Brain tissues collected in RNase-free tubes (see above) were 
subjected to RNA extraction by the Trizol method (Life Tech-
nologies, Rockville, MD, USA) for individual animals. The to-
tal RNA was treated with RQ1 DNase (Promega, Madison, WI, 
USA) to digest genomic DNA. Oligo(dT)15 primed the first-
strand eDNA synthesis was synthesized by AMY reverse tran-
scriptase (Promega). Group eDNA samples were synthesized 
by pooling together the RNA isolated from each animal. When 
necessary, eDNA from each rat was also synthesized to check 
the variation within group. The 5'-FAM labeled probes used in 
the Taqman real-time quantitative RT-PCR assay for GAPDH 
(endogenous control, Assay ID: Rn99999916_s1), GAP43 (As-
say ID: Rn00567901_m1), c-JUN (Assay 10: Rn0057299l_s1), 
neurocan (Assay ID: Rn00581331_m1), ephrinA5 (Assay ID: 
Rn005588118_s1), ephrinB1 (Assay ID: Rn00438666_sl) and 
glial fibrillary acidic protein (GFAP, Assay ID: Rn00566603 _ 
m1) were purchased from Applied Biosystems (Forster City, 
CA, USA). Reactions were performed in triplicates on AB 
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7900HT fast real time PCR system (Applied Biosystems). The 
relative level of mRNA expression in a given hemisphere was 
calculated as follows: 
mRNA = 2--<t.C T experimen1 group- t.CT sham w/o SDis)' 
where ~CT = ( CT, target- CT, Gapdh) 
lmmunoperoxidase Staining 
Cryosections were fixed first with 4% paraformaldehyde in 
PBS for 20 min at room temperature and incubated overnight 
at 4°C with the primary antibodies against GFAP (raised in the 
rabbit, Dako, Glostrup, Denmark) and neurocan (raised in the 
mouse, Millipore, Billerica, MA, USA) diluted in PBS contain-
ing 2% normal goat serum (Jackson ImmunoResearch, West 
Grove, PA, USA) and 0.03% Triton X-100 (Sigma Chemicals, 
St. Louis, MO, USA). The concentration for the GFAP antibody 
was 1 :6000; for the neurocan, it was 1 :2000. Sections were 
washed with PBS, incubated with the biotin-conjugated sec-
ondary antibody (Jackson ImmunoResearch), diluted at I :300 
for 1 hour at room temperature, and processed with the ABC 
immunoperoxidase staining method using Vectastain Elite kits 
(Vector Laboratories, Burlingame, CA, USA) and diamin-
obenzidine (Sigma) as the chromogen. Stained sections were 
analyzed and photographed with Leica OM 6000B microscope 
(Leica Microsystems, Wetzlar, Germany). 
Statistics 
Data were presented as mean ± standard deviation (s.d.). 
The significance of differences in means was assessed by in-
dependent !-test, one-way analysis of variance (ANOVA), and 
repeated-measures ANOVA (SPSS, 12.01 for Windows) where 
appropriate, AN OVA was followed by post hoc comparisons to 
determine group differences. The significance level was set at 
P values< 0.05. 
RESULTS 
Neurological Score and Changes in Vigilance States 
All animals subjected to MCAo did not exhibited neuro-
logical deficits according to Bederson's score,21 i.e., without 
forelimb flexion when lifted up by the tail and without cycling 
behavior, both at 12 h after stroke and the end of experiments. 
They walked normally but were somewhat drowsier than sham 
operated rats. 
Changes in the amount of BEG-defined vigilance states 
and in the episode length under the SDis procedure are listed 
in Table I and 2, respectively. SDpv12h carried out during the 
light phase resulted in an increase in SWS and PS during the 
following dark phase in b0th the ischemia/SDis and sham/SDis 
groups. In order to evaluate how SDpvl2h influenced the total 
amount of sleep on a daily base in the SDis experiment, values 
in the light phases were combined with those in the following 
dark phase (total in Table 1 ). The SWS amount in the ischemia/ 
SDis group reached almost the baseline level during day 1 and 
even tended to overshoot, although not statistically significant, 
during day 2, whereas in the sham group it was continuously 
below the baseline level by 11% to 12% (or 1.6 h) for 2 days. 
The difference between the 2 SDis-treated groups, i.e., isch-
emia/SDis 39.7 ± 3.7 vs. sham/SDis 28.2 ± 2.0 during day I 
and ischemia/SDis 47.9 ± 3.9 vs. sham/SDis 27.0 ± 1.6 during 
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day 2 (Table 1 ), was statistically significant (repeated-measures 
ANOVA, P < 0.001; independent t-test, P < 0.001), indicating 
an increased sleep propensity after ischemia. The total percent-
age of PS in the ischemia/SDis group decreased significantly 
from 10% of the baseline level (or 1.6 h) to 5% (or 0.8 h) dur-
ing day 1 and recovered slightly during day 2. In the sham/SDis 
group PS decreased slightly (~0.5 h) for 2 days. As an effect 
of sleep deprivation, the episode length for SWS and PS was 
reduced during the light phase (Ll, L2, and L3) but increased 
during the following dark phase for SWS (Dl) (Table 2). 
change in the ischemia!SDis group (Figure 2). The difference 
between the two SDis groups suggests that the delta activity be 
altered after brain injury. When data were averaged for 8 h in 
the light or dark phase, there were no significant changes for all 
groups (not shown). 
Effects of SDpv and SDis on Brain Damage 
Occlusion of the distal MCA resulted in an infarct located 
in the primary somatosensory cortex. While SDpv6h barely 
(P = 0.9) influenced the infarct volume, SDpv12h increased 
it by 40% (SDpv12h 82.8 ± 10.9 vs. control 59.2+13.9 mm3, 
P = 0.008) and SDis by 76% (SDis 58.8 ± 20.4 vs. control 
33.8 ± 6.3 mm3, P = 0.017), respectively (Figure 3A). The 
Delta power during SWS, a parameter for sleep pressure un-
der normal conditions, increased in the sham/SDis group at the 
first 2 h following SDpv (Figure 2). In contrast, there was no 
Table 1-Changes in wakefulness (W), slow wave sleep (SWS), and paradoxical sleep (PS) in the SDis experiment 
Experiment groups (n = 6 for each group) 
Baseline 
L 
D 
Ischemia w SDis 
WI SWS PSI w 
Ischemia w/o SDis 
SWSI PS 
ShamwSDis 
WI SWSI PSI 
39.3±5 51.6±4 9.1 ±3 
61.0±6 27.7±4 11.3±2 
Sham w/o SDis 
WI SWS PSI 
38.7±9 50.7±8 10.6±1 
69.4 ± 10 23.8 ± 9 6.8 ± 2 
total 
38.1 ±6 51.8±4 10.1 ±4 
56.5±4 33.5±3 10.0±4 
47.1 ± 4 42.9 ± 1 10.1 ± 3 
42.3 ± 6 48.9 ± 6 
59.6 ± 5 30.6 ± 3 
50.9±4 39.7±4 
8.8±2 
9.8±4 
9.3±2 50.1±4 39.6±3 10.2±2 54.1±7 37.3±7 8.7±1 
Day 1 
L 
D 
total 
Day2 
L 
D 
total 
Day3 
L 
83.8±6 15.8±6 0.4±1 
27.9±8 61.9±8 10.2±4 
39.2 ± 5 53.2 ± 5 
49.6 ± 7 43.3 ± 7 
7.6± 2 
7.1 ± 2 
55.8 ± 4* 39.7 ± 3 5.2 ± 2* 44.8 ± 5 47.9 ± 3* 7.3 ± 2 
77.0±5 22.8±5 0.2±0.3 39.1±10 54.1±8 6.8±3 
30.8 ± 3 57.8 ± 10 11.4 ± 5 55.1 ± 9 37.0 ± 9 7.9 ± 4 
53.2 ± 5* 47.9 ± 4 7.3 ± 2 47.5 ± 8 45.2 ± 5 7.4 ±3 
85.1 ±7 14.9±7 0.0±0 34.1 ±9 59.8±7 6.2±3 
96.3 ± 1 3.7 ± 1 0.0 ± 0.0 33.5 ± 3 56.3 ± 4 10.1 ± 2 
32.9 ± 4 52.3 ± 4 14.8 ± 2 53.9 ± 8 35.3 ± 6 10.8 ± 2 
64.6 ± 2* 28.2 ± 2* 7.4 ± 1* 
93.6 ± 2 6.4 ± 2 0.0 ± 0.0 
37.9 ± 6 47.5 ± 4 14.6 ± 2 
65.7 ± 2* 27.0 ± 2* 7.3 ± 1* 
42.2 ± 5* 46.3 ± 4 10.2 ± 1 
18.6±7 52.9±6 15.3±2 
58.0 ± 9 32.4 ± 7 9.5 ± 2 
42.8 ± 7* 42.8 ± 7 12.3 ± 2* 
94.0 ± 1 6.0 ± 1 0.0 ± 0.0 29.0 ± 2 57.4 ± 3 13.5 ± 2 
Values are mean± s.d. of percentages of recording hours (see Methods). L, the light phase (9:00-21 :00, 8 h of recording time 11:00-19:00); D, the dark phase 
(21 :00-9:00, 8 h of recording time 21 :00-5:00); Total, both the light and dark phase combined (16h); ip < 0.05 in one-way AN OVA followed by Turkey post hoc 
comparison; *P < 0.05 when compared with the baseline of the corresponding phase. 
Table 2-Changes in the episode length (s) of wakefulness (W}, slow wave sleep (SWS), and paradoxical sleep (PS) in the SDis experiment 
Experiment groups (n = 6 for each group) 
L 
D 
Baseline 
L1 
L2 
L3 
Baseline 
D1 
D2 
Ischemia w SDis 
WI SWSI PSI 
128 ± 19 141 ± 33 80 ± 13 
351* ± 82 69* ± 12 20* ± 22 
285* ± 93 96* ± 12 17* ± 29 
378* ± 104 73* ± 11 0.0* ± 0 
w 
347 ± 68 
SWSI PS 
141 ± 17 104 ± 30 
Ischemia w/o SDis ShamwSDis 
w SWSI PS SWSI PSI 
152 ± 44 119 ± 28 88 ± 20 143 ± 19 120 ± 16 69 ± 7 
182 ± 26 147 ± 24 93 ± 23 1044* ± 416 48* ± 3 0.0* ± 0 
196±30 186*±44 101±20 618*±150 47*±5 0.0*±0 
168 ± 40 215* ± 39 86 ± 27 604* ± 136 51*± 6 0.0* ± 0 
Wi SWSI PS Wi SWSI PS 
308±39 114±16 95±24 414 ± 124 116 ± 12 116 ± 10 
315 ± 174 297* ±54 110 ± 17 320 ±51 200* ± 40 108 ± 24 225* ± 36 206* ± 21 112 ± 12 
287±62 332±110 111±35 389*±55 167*±20 96±33 239±59 174*±19 113±8 
Sham w/o SDis 
w sws PS 
131 ± 21 125 ± 26 94 ± 15 
133 ± 12 144 ± 9 95 ± 16 
122±25 130±31 110±15 
122 ± 12 155 ± 16 103 ± 16 
w sws PS 
468 ± 162 120 ± 32 98 ± 17 
337 ± 26 144 ± 21 114 ± 19 
318 ± 72 120 ± 14 97 ± 10 
Values are means (s) ± s.d. of the episode length (see Methods). L, the light phase (9:00-21 :00, 8 h of recording lime 11 :00-19:00); D, the dark phase (21 :00-
9:00, 8 h of recording lime 21 :00-5:00); ip < 0.05 in One-way ANOVA followed by post hoc comparison; *P < 0.05 when compared with the baseline of the 
corresponding phase. 
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increased infarct area was found mostly at the level 5 and 6 
(Figure 4 ), where a less arterial anastomosis may account for 
the vulnerability. In parallel to the change in the infarct size, 
SDpv12h increased the number of damaged cells, visualized 
by the TUNEL positive staining, by 137% (SDpv12h 46.8 ± 15 
vs. control19.7 ± 7.7/mm2, P = 0.003) and SDis by 219% (SDis 
32.9 ± 13.2 vs. control 10.3 ± 2.5/mm2, P = 0.008), respectively 
(Figure 3B). There was no significant change in brain swelling 
in all experiments (Figure 3C). 
To investigate how the exacerbated brain damage was influ-
enced by changes in vigilance states, correlation of the infarct 
volume with altered W, SWS and PS was computed (Table 3). 
The results showed that the amount of W during day 1 was 
positively (Figure 5 and Table 3), and SWS negatively, corre-
lated with the increased infarct size (Table 3). In addition, the 
episode length for SWS was also negatively correlated with 
the infarct size during three days of SDpv (Ll - L3) and for 
PS during the first two days (L1 and L2). These results sug-
gest that both reduced and fragmented sleep contribute to the 
exacerbated stroke. 
An additional experiment was carried out to determine wheth-
er sleep rebound following SDpv would alleviate the exacerbated 
brain damage induced by sleep disruption. In this experiment rats 
(n = 6) were subjected to the same procedure as these for SD-
pv12h but allowed to sleep for 24 h following SDpv before sac-
rificed. There was no difference (P = 0.91) in the infarct volume 
between this group (81.5 ± 24.7 mm3) and the SDpv12h group 
(82.8 ± 10.9 mm3), indicating that the SDpv12h-induced brain 
damage during the acute phase of stroke was not reversible. 
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Figure 2-Effects of SDis on delta power (1-4 Hz) during slow wave sleep. 
Delta power was averaged for the first 2 h of each recording phase, and 
relative changes are plotted against the corresponding baseline (100%). 
Refer to Figure 1 for legends of L 1, L2, L3, D1, and D2. 
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Effects of SDis on Gene Expression 
Changes in expression of neuroplasticity-related genes are 
summarized in Figure 6. The most striking change was the dra-
matic increase (P < 0.001) of the growth-inhibiting gene neuro-
can in the ischemic (ipsilateral) hemisphere in the ischemia/ SDis 
group (14.3 ± 0.4-fold), compared with the ischemia/ without 
SDis (6.1 ± 0.1-fold) and both sham groups (~1-fold). Additional 
assays with individual RNA samples were carried out to assess 
the variation within groups and the result confirmed the SDis-
induced massive increase in neurocan expression (P < 0.003), 
with 11.03 ± 5.9-fold change in the ischemia/SDis group. SDis 
also induced a significant increase, although at smaller scale, in 
expression of another growth-inhibiting gene ephrinB 1 in the in-
jured hemisphere. In comparison, there was no SDis-induced fur-
ther change in expression ofGAP43, c-jun, and ephrinA5 (Figure 
6A). In the contralateral hemisphere (Figure 6B), SDis slightly 
increased (P < 0.05) expression of GAP43, c-jun, neurocan, and 
ephrinB 1, when compared with the ischemia/ without SDis. 
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Figure 3-Scatter plots showing effects of SDpv and SDis on the infarct 
volume (A), the number of TUNEL positive cells (B), and brain swelling 
(C) in individual animals. Horizontal lines present the mean values and 
analyzed by independent t-Ies! for each experiment. a, ischemia with 
sleep manipulation. b, ischemia without sleep manipulation. 
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{lower panel). The infarct areas are delineated by a black thin line. L 1 is 
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mm (Methods). B, Values are presented as mean± s.d. (n = 6 per group) 
and analyzed by independent t-test. *P < 0.05. 
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Figure 5-Correlation of the infarct volume with the amount of 
wakefulness (W) during the first day of the sleep disturbance. W values 
are the percentage of the total recording time including both the light and 
dark phase (Table 1, total). 
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Figure 6-Effects of SDis on expression of neuroplasticity-related genes. 
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ischemia w/o SDis group. bp < 0.05 when compared with the sham w. 
SDis group. 'P < 0.05 when compared with the sham w/o SDis group. 
One-way ANOVA(see F values, *P < 0.001) followed by Turkey post hoc 
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Table 3-Correlaton of infarct size with wakefulness (W), slow wave 
sleep (SWS), and paradoxical sleep (PS) in the SDis experiment. 
Infarct (mm3) Day RSq Pearson p 
1 0.587 0.766** 0.004 
W(%) 2 0.201 0.449 0.193 
0.592 -0.770** 0.003 
SWS(%) 2 0.246 -0.496 0.144 
0.007 -0.082 0.8 
PS(%) 
2 0.07 -0.264 0.461 
L 1 0.413 0.642* 0.024 
W episode length L2 0.513 0.716** 0.009 (s) 
L3 0.637 0.798** 0.002 
L 1 0.339 -0.582* 0.047 
SWS episode L2 0.352 -0.593* 0.042 length (s) 
L3 0.413 -0.642* 0.024 
L 1 0.453 -0.673* 0.016 
PS episode length L2 0.689 -0.830** 0.001 (s) 
L3 0.361 -0.601 0.039 
The amount of each vigilance states is presented as percentage of total 
recording time for each day. The episode length values are from the sleep 
deprivation period and refer to Figure 1 for L 1, L2, and L3. *P < 0.05; 
**P < 0.01 . 
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Expression of GFAP and Localization of Neurocan 
The growth-inhibiting gene neurocan has been known to 
be secreted by reactive astrocytes in response to various CNS 
injures,24 including ischemic stroke.25·2c' To assess whether the 
SDis-induced massive increase in neurocan expression was 
parallel to an increase in reactive astrocytes, we determined the 
expression of the astrocyte marker GFAP with Taqman assay 
and the cellular distribution of both GFAP and neurocan with 
immunoperoxidase staining in the ischemic hemisphere. The 
GFAP mRNA level increased, although at much smaller scale 
(2-fold) compared to the increase in the expression ofneurocan, 
in the ischemia without SDis group when compared with sham 
groups, and there was a slightly (but significantly) further in-
crease in the ischemia/SDis (Figure 7 A) . The immunoreactivity 
for both GFAP and neurocan was highly expressed in the peri-
infarct area (Figure 7B and C). 
Plasma Corticosterone level after SDpv12h and SDis 
In the SDpv 12h experiment, there was no significant change 
in the plasma co11icosterone level between the ischemia/SD-
pv 12h and its control group. In the SDis experiment, there was 
a significant decrease in groups subjected to SDis (ischemia and 
sham) when compared with groups without SDis. There was 
no significant difference between the ischemia/SDis and sham/ 
SDis (Figure 8). 
Changes in Body Weight 
Ischemia-operated rats tended to lose about 8-15 g or 5% of 
their body weight after surge1y, compared to 0-4 g of sham-op-
erated rats (Table 4). In neither the ischemia/SDpv 12h nor the 
Table 4-Changes in body weight after SDpv12h and SDis 
Groups 
baseline 
Experiment weight (g) Day 1* 
SDpv12h 
(n = 6 per 
group) 
Ischemia/ 
SDpv -14.3 ± 6.1 
262 ± 31 
Ischemia 
w/oSDpv -14.8 ± 6.1 
257 ± 23 
Day 2* Day 3* 
Ischemia/ 
SDis 
272 ± 17 
-12.2 ± 2.3•-b -17.0 ± 6.1' ·b -11.7 ± 3_7b 
SDis§ 
(n = 6 per 
group) 
Ischemia 
w/o SDis 
324 ± 25 
Sham/ 
SDis 
296 ± 24 
sham 
w/o SDis 
305 ± 14 
-8.2 ± 5.6b -10.5 ± 5.9 b -10.3 ± 6.4 
-4.0 ± 5.2 -7.8 ± 6.4 - 9.8 ± 6.4 
0.0 ± 5.2 -0.1 ± 5.3 1.3 ± 4.4 
*Values are means of difference from ihe baseline ± standard deviation. 
§Repeated measures ANOVA (F3 20 = 5.56, P = 0.006) followed by 
independent t-test. •p < 0.05 when· compared with sham/SDis. bp < 0.05 
when compared with the sham w/o SDis. 
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ischemia/SDis group did the body weight change significantly 
when compared with their paired ischemia/without SDpv l 2h or 
ischemia/without SDis group. 
DISCUSSION 
The findings that both sleep deprivation and repeated sleep 
disruption over 3 days aggravate acute brain damage (Figure 3 
885 
A Ischemic hemisphere 
Figure 7-Expression of the GFAP gene (A) and distribution of the 
immunoreactivity (ir) for GFAP (B) and neurocan (C, D). A: Values are 
presented as mean± s.d. One-way ANOVA (F 3_8 = 1013. *P < 0.001) 
followed by Games-Howell comparisons. •p < 0.05 when compared with 
the ischemia w/o SDis group. bp < 0.05 when compared with the sham 
w. SDis group. 'P < 0.05 when compared with the sham w/o SDis group. 
B. The GFAP-ir in the peri-infarct area. Note the highly expressed GFAP-
ir around the border of the infarct area. Bar, 100 ~m. C and D, High-
power photomicrograph illustrating expression of the neurocan-ir around 
parenchyma cells (marked with *). Note the substantially increased 
expression of the neurocan-ir in the peri-infarct area (C) compared with 
the weak staining in the contralateral cortex (D). Bars, 20 ~m . 
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Figure 8-Effects of SDpv and SDis on the plasma corticosterone level. 
Values are presented mean ± s.d. (n = 6 per group) and analyzed by 
either independent I-test in the SDpv12h experiment or one-way AN OVA 
followed by Turkey post hoc comparisons in the SDis experiment. 
•p < 0.02 when compared with the ischemia w/o SDis group. bp < 0.02 
when compared with the sham w/o SDis group. 
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and 4) provide the first direct evidence for a detrimental effect 
of sleep disruption on stroke. The underlying mechanism(s) re-
mains, however, to be specified. It has been known that high 
levels of plasma glucoc01iicoids after ischemia increase neuro-
nal vulnerability,27 whereas low levels reduce brain damage.28 
In this study, SDpv12h did not significantly alter the corticos-
terone level (Figure 8), while SDpv12h for consecutive 3 days 
(the SDis experiment) decreased the level (Figure 8). Thus, the 
plasma corticosterone level does not appear to be related to the 
worsened brain damage after SDpv/SDis. Ischemic stroke, due 
to a sudden reduction of blood flow, triggers a series of events, 
including energy failure, excitotoxicity, free radical generation, 
and inflammation-a cascade that determines the fate of infarc-
tion.4·5 Short-term SDpv has been shown to elevate the brain 
temperature29 and brain energy consumption, evidenced by in-
creasing 2-deoxyglucose uptake8 and decreasing the level of 
brain glycogen, the principal energy store in the brain.6 Short-
term SDpv also increases the extracellular glutamate concentra-
tion,9 glutamate receptor levels and neuronal activities,30 which 
would worsen ischemia-induced excitotoxicity. Furthermore, 
prolonged SDpv has been shown to decrease levels of some 
antioxidative stress markers, such as glutathione, glutathione 
peroxidase, and superoxide dismutase,31 '33 which in turn could 
intensify cell damage caused by free oxygen radical in the isch-
emia site. Prolonged SDpv or sleep restriction also increases 
levels of certain pro inflammatory cytokines such as IL-l 13, IL-
6, and TNFa}0•11 that play an important role in the inflamma-
tory phase of cerebral ischemia.34 Taken together, substantial 
experimental evidence suggests that SDpv/SDis could aggra-
vate stroke through potentiation of mechanisms implicated in 
its pathophysiologyY Further studies are needed to identify es-
sential contributors. 
SDis altered the expression of several genes that mediate 
initiation of post-stroke axonal sprouting at the early phase af-
ter stroke (Figure 6). The substantial changes occurred in the 
ischemic hemisphere where SDis induced a massive increase 
in expression of the growth-inhibiting gene neurocan (Figure 
6). Neurocan is one of major chondroitin sulfate proteoglycans 
(CSPGs) and secreted by reactive astrocytes in response to vari-
ous CNS injures.24-26 Its inhibitory property to axonal growth has 
been demonstrated both in vitro35·36 and in vivo,26·37 possibly by 
activation of the Rho/ROCK pathway.38 Around the border of 
the infarct area, densely packed reactive astrocytes (Figure 7B) 
together with growth-inhibitory molecules including neurocan 
(Figure 7C) form a physical and biochemical barrier that hin-
ders the neuronal reconnection. Interestingly, the present data 
that SDis increases neurocan expression after ischemic stroke 
is in line with our previous observations that the sleep stimulant 
gamma-hydroxybutyrate has an opposite (decrease) effect on the 
ischemia-induced neurocan expression, 16 suggesting that neuro-
can be an important molecule implicated in the sleep-modulated 
post-stroke brain plasticity. In this context, large scale screen-
ing ofneuroplasticity-related genes and their protein products is 
needed to understand molecule mechanisms involved in sleep-
modulated neuroplasticity after ischemic stroke. In addition, it 
remains to demonstrate the influence of sleep disruption on post-
stroke axonal sprouting and finally on functional recovery. 
In summary, this study demonstrate that at the early phase of 
stroke, sleep disruption aggravates brain damage and increases 
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expression of genes that inhibit post-stroke axonal sprouting. 
Thus, prevention of sleep disturbances and improvement of 
sleep quality may become a new therapeutic window to im-
prove outcome. 
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